Follow-up reactions triggered by the procurement of quail-type drugs

As the Anhui Bengbu official responded to a series of questions posed by the “buy procurement” business, the focus of industry attention gradually shifted to a series of follow-up reactions that the incident may bring.

It can be seen that Xu's "promotional procurement" revealed some new ideas at the government level in the implementation. This change may be fatal for pharmaceutical companies. On the one hand, “quantity procurement” is classified and purchased according to different products and attributes, and the basis for grouping and price reduction is the analysis and evaluation of the expert team under the official support, and the classified procurement ideas are implemented at the local level; Hospitals are really involved in procurement, making the academic ability of experts have a valuable role in drug procurement, ie, an exclusive product or an exclusive product that does not mean that it is irreplaceable in clinical application. The real scarcity of products may be It is a decisive factor for the future tender procurement, otherwise the competitive pressure may increase significantly.

Look at Anhui or see the country?

Recalling the procurement process, you can find that the procurement leader is prepared, from the notification of the inquiry issued to the completion of procurement in one go. According to the official announcement, the procurement work was completed in only one day. Among them, more than 20 kinds of pharmaceutical products with a single variety and quotation were purchased and the price of drugs dropped by 25%; 5 companies outside the city and 5 companies in the city, including a total of 10 distribution companies, were selected as successful bidders. More than 2,600 kinds of drugs were involved in the centralized procurement of pharmaceuticals. The concentration of successful companies increased significantly. The rate of successful bids for companies with large scale and good quality control increased significantly. The price of winning drugs also decreased markedly. The price dropped by 17.24%, a maximum decrease of 22.5%, and the profit amount was more than 80 million yuan.

According to the previous request, the procurement was included in the single-category catalog of 30 varieties. If the company does not reach a 25% concession rate, it will not be able to access 94 public medical institutions in the city.

The accurate data of “25% price reduction” has caused a lot of skepticism in the industry, but this does not affect the official implementation of this requirement. At the same time when the bidding results are completed, the official announcement has been made because of the inclusion of single varieties. The prices of medicines in the Catalogue with Volume Purchase have not reached a price reduction of 25%, and all of its medicines are not permanently sold in all public medical institutions in Handan City. The involved manufacturers include Shandong Danhong Pharmaceutical, Beijing Sihuan Pharmaceutical, and Harbin Songhe Pharmaceutical. , Jiangsu Osel Kang Pharmaceutical, Dali Pharmaceutical, Hongri Pharmaceutical, GSK, etc., all well-known brand manufacturers. As a result, this year's attention to "taking quantity" has been pushed to a high point.

There are two reasons for becoming a focus in the industry: First, the government has clearly defined price cuts in "quantity procurement," and it has a hard-line attitude and precision. Second, does the hard-line only represent Yao or Anhui? In fact, no matter how much the prices are reduced, it is only a prefecture-level city after all. However, is Anhui Province doing some temptations behind the drastic changes in the “promotional procurement” link? Anhui Province is one of the important pilots of national drug bidding reform. This is the key to the nation’s concern.

“Before, the documents at the State Department level have been clarified and support for the establishment of joint purchasing agencies at the city level, which means that there is no need to consider political risks at the local level,” said a vice president of sales of a state-owned enterprise in Sichuan. However, the country’s specific implementation methods and content for procurement bodies are not clearly required. Since the documents were issued, Anhui, Zhejiang, Sichuan, Chongqing and other places have tried a variety of consortiums and “batch procurement” models. The second price reduction is basically used at the same time.

“From the current point of view, the nation’s drug procurement situation has exerted great pressure on pharmaceutical companies. In the past, it may have been more in the field of pharmaceuticals. In the future, it will be more in the field of medical insurance products, whether it is tendering or 'procuring with scale'. Price reduction has become a clear theme, and we hope that we can have a precise market strategy and expand the market share as much as possible under the circumstances where Rangli is inescapable,” said a pharmaceutical salesman in Hebei.

Classification procurement ideas refinement

In fact, from the series of games between the bidding company and the government, it can be seen that the leading party's thinking on drug procurement has entered a new stage. From the national perspective, the concept of classified tendering has been very clear, while the tender procurement has emphasized the special treatment of special varieties, and it can even be considered as a refinement of classified procurement ideas.

First of all, according to the industry’s 25% price cuts, which were loudly questioned by the industry, the head of the Medical and Health Branch of the Bengbu City Health Planning Commission said in response to queries that the price cuts of 20% of the 30 drugs included in the single-item catalogue were The figures obtained through the collective argumentation of experts are considered by the government to be entirely within the scope of the enterprise. As a result, companies are required to achieve this reduction. According to the reporter's understanding, in the process of inquiry with pharmaceutical companies, the company consulted with related companies. The remaining products, despite their substantial price reductions, are still inferior to those on the single-item catalog, and they do not require uniform prices.

In addition, companies need to pay special attention to the fact that the above-mentioned person in charge of the medical and health section of the Handan City Health Planning Commission also mentioned that the individual products targeted at the drug companies being blocked belong to exclusive products, and that they will actively seek alternative products. . Does this release a signal: Officials are also aware that even in exclusive varieties, alternative products exist in clinical applications.

This may be the biggest difference from the criteria used in the past for tendering under the generic name. If the implementation of a procurement approach to disease treatment or departmental applications is implemented, how much market competition pressure will be added to the exclusive or exclusive products, and even to the original products with less approval?

In the face of changes in the pattern of drug procurement, how should companies choose?

According to news from related parties, the officials previously had communicated with the drug companies that had been banned, but they did not reach a consensus on a 25% price reduction. The head of government affairs of foreign-funded enterprises told reporters that the products that were banned were all large manufacturers. Manufacturers do not want to see such a prefecture-level market, undermining the hard work to create a price system, so as to avoid damage to the national market due to the linkage of tender prices.

On the other hand, in addition to manufacturers who agreed to cut prices from the outset, according to the official website of the company, after the results of the bidding were announced, some single-variety manufacturers contacted the officials. They applied for consent to be included in the transaction list according to the request for quotation. The varieties include oxiracetam injection, pantoprazole sodium injection, deproteinized calf blood extract injection, cefozetone sodium injection for injection, and thrombosis (freeze-dried) for injection. The reason why these products ultimately "software" may also be closely related to the scarcity and irreplaceability of their products. The firm attitude of the companies that have been banned is sufficient confidence in the scarcity of the product market, or is it waiting for the market to wait and see? unknown.